– SWITZERLAND, Geneva – Medimaps Group, a Swiss and Global MedTech company specializing in image processing software for assessing bone health, announced the appointments to its Board of Directors of Meinhard Schmidt as Chairman alongside Anne Le Grand joining as an Independent Director.
Concurrently, five additional board members have also been named, bolstering the Board’s investment and clinical policy expertise.
“I’m pleased to welcome Meinhard and Anne to our Board of Directors. Meinhard’s global leadership roles in diagnostics at Philips and Roche Diagnostics—and Anne’s work leading medical imaging and healthcare businesses including AI solutions—offer Medimaps significant expertise and acumen to support our immediate growth and shape our future success,” said CEO, Prof. Didier Hans.
About Meinhard F. Schmidt
Meinhard Schmidt held senior leadership roles at Philips and Roche Diagnostics where he held various global senior leadership roles in Patient/Diabetes-Care, Laboratory- and PoC-Diagnostics. After that, he worked as an executive at Institute Straumann as a Business Unit head and then CEO, where he was responsible for their digital group for the worldwide “Digitalization” of the Dental industry. Currently, he holds board and advisory roles for public and private MedTech/Digital Health companies, focusing on growth and commercialization.
About Anne Le Grand
Anne Le Grand served as global VP of IBM and General Manager for Watson Health Imaging, Oncology, Genom,ics and Life SciencesBeforeto IBM, she held executive leadership positions at Philips Health Systems, leading the Therapeutic Care and Ultrasound division before to that Ms. Le Grand served as SVP Healthcare of Global X-ray for GE Healthcare, where she successfully launched and refreshed portfolios across the global x-ray, mammography, and metabolic bone disease businesses. She currently holds board and consulting roles for public and private sector healthcare companies.
About Dr. Robert Schier
Dr. Robert Schier (Ph.D.) Senior Investment Director at Zürcher Kantonalbank Asset Management (Swisscanto Private Equity). Dr. Schier sits on the Boards of Directors of many life sciences companies.
He holds a degree in pharmacy from the University of Vienna and a Ph.D. in biotechnology from the University of Natural Resources and Life Sciences, Vienna.
About Dr. Myoung-Ok Kwon
Dr. Myoung-Ok Kwon (Ph.D.) investment partner at Swisscom and leading digital health investments. She has 20 years of experience in healthcare investment and pharma research. At Novartis, she was responsible for research strategy and planning and portfolio review.
She holds a Ph.D. in biochemistry and molecular genetics from the Friedrich Miescher Institute, Novartis, and the University of Basel.
About Georgette Schmid
Georgette Schmid, investment manager at Helvetica Capital AG Before joining Helvetica Capital, Mrs. Schmid was working in the business development and investment division within the consumer goods and hotel industry.
She holds a Master of Law from the University of Zurich and a Master of Business Administration (MBA) from Ecole hôtelière de Lausanne.
About Prof. Didier Hans
Prof. Didier Hans (Ph.D.) has been CEO of Medimaps Group since 2012. He has 25+ years of experience in dual-energy x-ray absorptiometry (DXA), bone macro- and microarchitecture, ultrasound imaging techniques, and body composition assessment. He teaches worldwide bone and body composition imaging and osteoporosis.
He holds a Ph.D. in medical physics and an Executive MBA from HEC Geneva.
About Sarah Lumb
Sarah Lumb, co-founder and managing partner of Mission Global, a freight specialist in event logistics. She played an integral part in the creation of the group, now with nearly 200 partner offices worldwide. Her business interests extend to two other companies–Ethical Pharmaceutical Consulting Service SA and Kanis SA–that have investments across a diverse range of industries, but with a particular interest in biotech, medical device, and other high-technology companies.
About Medimaps Group
Medimaps Group’s medical imaging software applications based on patented multi-purpose technology with artificial intelligence capabilities provide healthcare solutions that fit seamlessly into the workflow for the benefit of the patient. TBS iNsight™ (Osteo) has been used for years in clinical practice worldwide in the field of osteoporosis. It has become the new gold standard for bone texture assessment in routine clinical practice. TBS has gained international recognition with more than 900 peer-reviewed scientific publications and is included in many guidelines and used by more than 30,000 physicians worldwide including leading healthcare institutions.
For more, visit https://www.medimapsgroup.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.